Company: APXIF
Filing Date: 2025-06-11
Form Type: 10-Q
Source: 0001213900-25-053185
Chunk: 52

Company: APx Acquisition Corp. I
Filing Date: 2025-06-11
Form: 10-Q
Item: Part I, Item 1
Chunk 52
---
 or prior to the applicable deadline specified in the Business Combination Agreement.

 34

In the event that the
Business Combination Agreement is terminated, all Transaction Expenses incurred in connection with the Proposed Business Combination shall
be paid by the party incurring such Transaction Expenses. If the Transactions are consummated, (a) OmnigenicsAI shall pay or cause
to be paid (i) the SPAC Transaction Expenses, subject to the SPAC Transaction Expenses Cap, and (ii) the Company Transaction
Expenses at the Closing; and (b) Templar Sponsor shall pay or cause to be paid, (i) all unpaid SPAC Transaction Expenses in
excess of the applicable SPAC Transaction Expenses Cap, (ii) any expenses incurred by the Company in its pursuit of potential acquisition
or business targets other than the Target Companies or that were not incurred by the Company in connection with or in furtherance of the
Proposed Business Combination and (c) all fees and expenses incurred by the Company solely relating to the extension proposals approved
by the shareholders of the Company on February 27, 2023, September 7, 2023 and December 8, 2023, which extended the date
by which the Company must consummate a business combination.

The foregoing description
of the Business Combination Agreement is qualified in its entirety by reference to the full text of the Business Combination Agreement,
a copy of which is included as an exhibit to this Quarterly Report.

Certain Agreements Related to the Business
Combination Agreement

MultiplAI Share Purchase Agreement

On March 13, 2024,
Heritas Ltd., a Cayman Islands exempted company (“Parent”), MultiplAI and the holders (the “MultiplAI Shareholders”)
of ordinary shares, par value £0.0001, of MultiplAI and any other equity commitments or equity securities of MultiplAI, including
any securities or commitments convertible into, exchangeable or exercisable for, or representing the right to subscribe for, any such
ordinary shares of MultiplAI (such securities, the “MultiplAI Shares”) entered into that certain amended and restated share
purchase agreement (the “MultiplAI SPA”) relating to the sale and purchase of all of the ordinary shares of MultiplAI and,
if required under the MultiplAI SPA, all of the MultiplAI Shareholders’ rights and interest in certain equity related agreements
and convertible securities, as well as any related anc